💊 Ustekinumab-associated morphoea: systematic review of the literature and a real-world case

Sousa et al.

Read the full article here: www.drugsincontext.com/ustekinumab-...

#Dermatology #Immunology #Pharmacovigilance #Ustekinumab #Biologics @medsky.social @me.pharmsky.app

CivicaScript Expands Access to Affordable Insulin and Biosimilars in the U.S. CivicaScript unveils new low-cost insulin and biosimilars aimed at providing better access for patients dealing with chronic conditions, enhancing affordability.

CivicaScript Expands Access to Affordable Insulin and Biosimilars in the U.S. #United_States #Lehi,_Utah #CivicaScript #Ustekinumab #Insulin_Glargine

Accord BioPharma's IMULDOSA® Receives Preferred Status in National Formularies Accord BioPharma's IMULDOSA® has been added to Express Scripts' national formularies, enhancing patient access to this vital therapy for chronic conditions.

Accord BioPharma's IMULDOSA® Receives Preferred Status in National Formularies #United_States #Raleigh #Accord_BioPharma #Ustekinumab #IMULDOSA®

¿#Ustekinumab en Enfermedad de #Crohn pediátrica?

✔️Eficaz en #niños con EC que no han respondido al tratamiento con fármacos biológicos de 1ª línea
📌Evidencia limitada y basada casi exclusivamente en estudios observacionales

#Preevid

👉👉https://www.murciasalud.es/preevid/26598

Accord BioPharma Launches IMULDOSA® at Unmatched Price for Patients Needing Treatment Accord BioPharma introduces IMULDOSA®, a biosimilar to STELARA®, with a significant price reduction to enhance accessibility for patients in need.

Accord BioPharma Launches IMULDOSA® at Unmatched Price for Patients Needing Treatment #United_States #Raleigh #Accord_BioPharma #Imuldosa #Ustekinumab

Stelara uploaded My one decent vein! It does sound like some business or utility software offering, but there’s few single users could afford €12000 per year for software-as-a-service. Yesterday I got my loading do…

msmartinecom.wordpress.com/2025/05/23/s... #blog #crohns #stelara #ustekinumab # ibd

Biocon Biologics Expands Access for Yesintek™, Benefiting Over 100 Million in the U.S. Biocon Biologics has successfully established agreements for its biosimilar Yesintek™, increasing access to more than 100 million lives in the U.S. marketplace.

Biocon Biologics Expands Access for Yesintek™, Benefiting Over 100 Million in the U.S. #United_States #Biocon #Bridgewater #YESINTEK™ #Ustekinumab

3 days until I can have my ustekinumab for my IBD. It's just dawned on me why I'm feeling so awful! I'm going to bed with tea and a hot water bottle. #IBD #ustekinumab